SCHEMBL8427598

SCHEMBL8427598

CC(C)(C)OC(=O)Nc1ccccc1C(=O)c1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.52
▸ TP53 P04637 1/20 0.51
▸ BDKRB1 P46663 1/20 0.51
▸ TSHR P16473 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ BCL2 P10415 1/20 0.46
▸ IDO1 P14902 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13359744 0.86 CYP17A1 (0.49) NAMPTBDKRB1RXFP1IDO1RAB9A
SCHEMBL2703465 0.85 ALDH1A1 (0.54) TP53BDKRB1MAPTRXFP1IDO1
SCHEMBL19857846 0.85 CCR9 (0.57) NAMPTTP53MAPTRAB9AALDH1A1
SCHEMBL18126653 0.84 KDM4C (0.52) NAMPTBCL2RAB9AKMT2A
SCHEMBL8241253 0.79 BDKRB1 (0.54) TP53BDKRB1MAPTRXFP1KDM4E
SCHEMBL8939407 0.78 PDK1 (0.61) BDKRB1TSHR
SCHEMBL16109601 0.78 RXFP1 (0.48) TP53BDKRB1MAPTRXFP1RAB9A
SCHEMBL30816984 0.76 ALDH1A1 (0.52) RXFP1IDO1KDM4EALDH1A1KMT2A
SCHEMBL18228021 0.76 NAMPT (0.50) NAMPTMAPTBCL2RAB9AALDH1A1
SCHEMBL479747 0.76 NAMPT (0.58) NAMPTKDM4ERAB9AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718795-B2 Succinoylamino benzodiazepines as inhibitors of aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2010-05-18 — — US disclosed
US-20090069293-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-12 — — US disclosed
US-7456172-B2 Succinoylamino benzodiazepines as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-25 — — US disclosed
US-20080207602-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-08-28 — — US disclosed
US-7304049-B2 Succinoylaminobenzodiazepines as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
US-20060122169-A1 Succinoylamino benzodiazepines as inhibitors of Abeta protein production DUPONT PHARMACEUTICALS (US) 2006-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069293-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION GABRA5, APP, GABRE NAMPT 3110/4885TP53 4043/4885BDKRB1 2840/4885
US-20080207602-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION BACE1, APP, GABRE NAMPT 3303/4885TP53 3899/4885BDKRB1 2218/4885
US-20060122169-A1 Succinoylamino benzodiazepines as inhibitors of Abeta protein production BACE1, APP, GABRE NAMPT 3303/4885TP53 3899/4885BDKRB1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback